Etonogestrel-releasing contraceptive implant in a patient using thalidomide for the treatment of erythema nodosum leprosum: a case report

References

• Robbins G, Tripathy VM, Misra VN, et al. Ancient skeletal evidence for leprosy in India (2000 B.C.). PLoS One. 2009;4(5):e5669.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global leprosy (Hansen disease) update, 2019. time to step-up prevention initiatives [Internet]. 2020; [cited 2021 Aug 31]. Available from: https://www.who.int/publications/i/item/who-wer9536.
   Google Scholar
• Upputuri B, Pallapati MS, Tarwater P, et al. Thalidomide in the treatment of erythema nodosum leprosum (ENL) in an outpatient setting: a five-year retrospective analysis from a leprosy referral Centre in India. PLoS Negl Trop Dis. 2020;14(10):e0008678.
   PubMed Web of Science ®Google Scholar
• Eichelmann K, González González SE, Salas-Alanis JC, et al. Leprosy. An update: definition, pathogenesis, classification, diagnosis, and treatment. Actas Dermosifiliogr. 2013;104(7):554–563.
   PubMedGoogle Scholar
• Vargesson N. Thalidomide-induced teratogenesis: history and mechanisms. Birth Defects Res C Embryo Today. 2015;105(2):140–156.
   PubMedGoogle Scholar
• Ministério da S, Agência Nacional de VS. Resolução RDC no 11, de 22 de março de 2011. Dispõe sobre o controle da substância talidomida e do medicamento que a contenha. [Internet]. 2011; [cited 2021 Mar 28]. Available from: http://bvsms.saude.gov.br/bvs/saudelegis/anvisa/2011/res0011_21_03_2011.html.
   Google Scholar
• Ferreira-Filho ES, de Melo NR, Sorpreso ICE, et al. Contraception and reproductive planning during the COVID-19 pandemic. Expert Rev Clin Pharmacol. 2020;13(6):615–622.
   PubMed Web of Science ®Google Scholar
• Lange J, Teal S, Tocce K. Decreased efficacy of an etonogestrel implant in a woman on antiepileptic medications: a case report. J Med Case Rep. 2014;8:43.
   PubMedGoogle Scholar
• Sunaga T, Cicali B, Schmidt S, et al. Comparison of contraceptive failures associated with CYP3A4-inducing drug-drug interactions by route of hormonal contraceptive in an adverse event reporting system. Contraception. 2021;103(4):222–224.
   PubMed Web of Science ®Google Scholar
• Drummond P. D M, Santos R. D, Carvalho GO, et al. Adverse events in patients with leprosy on treatment with thalidomide. Rev Soc Bras Med Trop. 2019;52(e20180385):1–6.
   Google Scholar
• Olsson SE, Odlind V, Johansson E. Clinical results with subcutaneous implants containing 3-keto desogestrel. Contraception. 1990;42(1):1–11.
   PubMed Web of Science ®Google Scholar
• Díaz S, Pavez M, Moo-Young AJ, et al. Clinical trial with 3-keto-desogestrel subdermal implants. Contraception. 1991;44(4):393–408.
   PubMed Web of Science ®Google Scholar
• Ali M, Bahamondes L, Bent Landoulsi S. Extended effectiveness of the Etonogestrel-Releasing contraceptive implant and the 20 µg Levonorgestrel-Releasing intrauterine system for 2 years beyond U.S. Food and drug administration product Labeling. Glob Health Sci Pract. 2017;5(4):534–539.
   PubMed Web of Science ®Google Scholar
• Graesslin O, Korver T. The contraceptive efficacy of implanon: a review of clinical trials and marketing experience. Eur J Contracept Reprod Health Care. 2008;13(Suppl 1):4–12.
   PubMed Web of Science ®Google Scholar
• Harrison-Woolrych M, Hill R. Unintended pregnancies with the etonogestrel implant (implanon): a case series from postmarketing experience in Australia. Contraception. 2005;71(4):306–308.
   PubMed Web of Science ®Google Scholar
• Murayama N, van Beuningen R, Suemizu H, et al. Thalidomide increases human hepatic cytochrome P450 3A enzymes by direct activation of the pregnane X receptor. Chem Res Toxicol. 2014;27(2):304–308.
   PubMed Web of Science ®Google Scholar
• Murayama N, Kazuki Y, Satoh D, et al. Induction of human cytochrome P450 3A enzymes in cultured placental cells by thalidomide and relevance to bioactivation and toxicity. J Toxicol Sci. 2017;42(3):343–348.
   PubMed Web of Science ®Google Scholar
• Scheffler MR, Colburn W, Kook KA, et al. Thalidomide does not alter estrogen-progesterone hormone single dose pharmacokinetics. Clin Pharmacol Ther. 1999;65(5):483–490.
   PubMed Web of Science ®Google Scholar
• Trapnell CB, Donahue SR, Collins JM, et al. Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone. Clin Pharmacol Ther. 1998;64(6):597–602. Dec
   PubMed Web of Science ®Google Scholar
• Madden T, Secura GM, Nease RF, et al. The role of contraceptive attributes in women’s contraceptive decision making. Am J Obstet Gynecol. 2015;213(1):46.e1–46.e6.
   PubMed Web of Science ®Google Scholar
• Trussell J. Contraceptive efficacy. Arch Dermatol. 1995;131(9):1064–1068.
   PubMedGoogle Scholar
• Croxatto HB. Mechanisms that explain the contraceptive action of progestin implants for women. Contraception. 2002;65(1):21–27.
   PubMed Web of Science ®Google Scholar
• Davies GC, Feng LX, Newton JR, et al. Release characteristics, ovarian activity and menstrual bleeding pattern with a single contraceptive implant releasing 3-ketodesogestrel. Contraception. 1993;47(3):251–261.
   PubMed Web of Science ®Google Scholar
• Bennink HJ. The pharmacokinetics and pharmacodynamics of implanon, a single-rod etonogestrel contraceptive implant. Eur J Contracept Reprod Heal Care off J Eur Soc Contracept. 2000;5(Suppl 2):12–20.
   PubMedGoogle Scholar
• Di Carlo C, Guida M, De Rosa N, et al. Bleeding profile in users of an etonogestrel Sub-dermal implant: effects of anthropometric variables. An observational uncontrolled preliminary study in italian population. Gynecol Endocrinol. 2015;31(6):491–494. Jun
   PubMed Web of Science ®Google Scholar
• Ferreira JM, Nunes FR, Modesto W, et al. Reasons for Brazilian women to switch from different contraceptives to long-acting reversible contraceptives. Contraception. 2014;89(1):17–21.
   PubMed Web of Science ®Google Scholar